American Society of Clinical Oncology begins development of CancerLinQ

Laura Pedulli | | Health Exec | Economics

 

American Society of Clinical Oncology is working to develop a clinical decision support and analytics tool to improve delivery of care to patients with cancer.

The platform, CancerLinQ, is scheduled for release in late 2015. So far, eight oncology practices around the U.S. have signed agreements with CancerLinQ to provide patient records for the first version of CancerLinQ. These include Inova Comprehensive Cancer & Research Institute, South Coast Centers for Cancer Care, New England Cancer Specialists, Medical Oncology Hematology Consultants, PA Cancer Treatment Centers of America, Marin Cancer Care, Space Coast Cancer Center and Michiana Hematology-Oncology, according to a press release.

These practices, which include community practices and large cancer centers, have engaged CancerLinQ to aggregate and analyze a wide range of data and provide reports for quality improvement. Insights gathered from the data will establish the groundwork for developing the full system, which will be open to all U.S. oncology practices, according to ASOC.

CancerLinQ LLC will continue to advance the overall development of the platform, while ASCO will maintain control over the data, service, and products that stem from the platform including clinical decision support tools and analyses.

Visit the website. 

 

Laura Pedulli

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.